Literature DB >> 11345199

Differential susceptibility of quiescent CD4+ lymphocytes to syncytial-inducing and non-syncytial-inducing isolates of HIV-1.

P Auewarakul1, S Louisirirotchanakul, S Srisurapanon, R Phonarknguen, R Sutthent.   

Abstract

It is generally believed that quiescent CD4+ T cells are not susceptible to HIV-1 infection. However, infection of unstimulated peripheral mononuclear cells by syncytial-inducing (SI) viruses has been shown to be much more efficient than with non-syncytial-inducing (NSI) viruses. This suggested that SI, CXCR4-tropic viruses may be able to infect quiescent CD4+ T cells. We studied the infection of highly purified quiescent CD4+ T cells by SI and NSI viruses. In this article we show that although NSI viruses failed to significantly infect quiescent cells, SI viruses consistently infected these cells and produced viruses upon cellular activation by interleukin-2, 2 to 7 days after initial infection. To examine whether the difference was the result of viral or host factors, we purified CCR5+ quiescent CD4+ T cells and showed that these cells can be infected by dual tropic (R5X4) but not by R5 virus. This indicated that CCR5+ quiescent T cells were also susceptible to HIV-1 infection, and the failure of NSI, CCR5-tropic viruses to infect quiescent cells may be due to some intrinsic properties of these viruses.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11345199     DOI: 10.1007/BF02981958

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  10 in total

1.  Increase in activated CD4+ lymphocytes with CCR5 and CXCR4 in HIV type 1-infected persons.

Authors:  P Auewarakul; K Sangsiriwut; K Pattanapanyasat; S Suwanagool; C Wasi
Journal:  AIDS Res Hum Retroviruses       Date:  1999-10-10       Impact factor: 2.205

2.  Antibody-mediated neutralization of primary isolates of human immunodeficiency virus type 1 in peripheral blood mononuclear cells is not affected by the initial activation state of the cells.

Authors:  J Y Zhou; D C Montefiori
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

3.  Highly purified CD25- resting T cells cannot be infected de novo with HIV-1.

Authors:  C S Chou; O Ramilo; E S Vitetta
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

4.  Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection.

Authors:  T W Chun; L Carruth; D Finzi; X Shen; J A DiGiuseppe; H Taylor; M Hermankova; K Chadwick; J Margolick; T C Quinn; Y H Kuo; R Brookmeyer; M A Zeiger; P Barditch-Crovo; R F Siliciano
Journal:  Nature       Date:  1997-05-08       Impact factor: 49.962

5.  Neutralization of primary and T-cell line adapted isolates of human immunodeficiency virus type 1: role of V3-specific antibodies.

Authors:  S Beddows; S Louisirirotchanakul; R Cheingsong-Popov; P J Easterbrook; P Simmonds; J Weber
Journal:  J Gen Virol       Date:  1998-01       Impact factor: 3.891

6.  Progression to the G1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells.

Authors:  Y D Korin; J A Zack
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

7.  Simultaneous three-color analysis of the surface phenotype and DNA-RNA quantitation using 7-amino-actinomycin D and pyronin Y.

Authors:  K Toba; E F Winton; T Koike; A Shibata
Journal:  J Immunol Methods       Date:  1995-06-09       Impact factor: 2.303

8.  HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure.

Authors:  J A Zack; S J Arrigo; S R Weitsman; A S Go; A Haislip; I S Chen
Journal:  Cell       Date:  1990-04-20       Impact factor: 41.582

9.  Highly purified quiescent human peripheral blood CD4+ T cells are infectible by human immunodeficiency virus but do not release virus after activation.

Authors:  S Tang; B Patterson; J A Levy
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

10.  HIV-1 replication is controlled at the level of T cell activation and proviral integration.

Authors:  M Stevenson; T L Stanwick; M P Dempsey; C A Lamonica
Journal:  EMBO J       Date:  1990-05       Impact factor: 11.598

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.